COMPANY PROFILE

Wuhan Ruijian Pharmaceutical Technology

Explore full profile

Innovative cell therapies targeting major incurable diseases with fast-acting, disease-reversing solutions

Wuhan, ChinaFounded 2017Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2026

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Wuhan Ruijian Pharmaceutical Technology

iRegene Therapeutics is at the forefront of developing groundbreaking cell therapies aimed at curing major incurable diseases. The company specializes in chemically defined cell therapy, a cutting-edge approach that reprograms cell fate or function to treat degenerative diseases. iRegene's primary clients are patients suffering from severe and currently untreatable conditions. Operating in the biotechnology and healthcare market, iRegene employs a business model centered on research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through the sale of these innovative treatments, as well as potential partnerships and licensing agreements with larger pharmaceutical companies. The company is committed to making these fast-acting, disease-reversing therapies as accessible as possible to patients in need.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Wuhan, China
Open positions: None listed
Dealroom signal: 58.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Wuhan Ruijian Pharmaceutical Technology.

See all news

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Jun 2026	$29M	$116M	Guanghe VC	↗
SERIES BOther financing	Sep 2025	—	—	Innovation Capital · NLVC · Yuanxi Haihe Fund	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Wuhan Ruijian Pharmaceutical Technology website traffic

Latest recorded traffic for Wuhan Ruijian Pharmaceutical Technology is 1.4K monthly website visits, up 1172.7% over the last three months.

Latest monthly visits1.4K 3-month web change+1172.7%

Monthly website visitsMay 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RTRay TherapeuticsDeveloping optogenetic gene therapies to restore vision in patients with blinding diseases	Berkeley, United States	Operational	49	$235M	$500M
OTone-carbon TherapeuticsFocuses on developing treatments for cancer, inflammation, and autoimmune diseases	Stockholms kommun, Sweden	Operational
NBNexEos BioNon-invasive imaging agent for diagnosing and managing Eosinophilic Esophagitis, enhancing patient care and disease monitoring	Pottstown, United States	Operational
PHPhilogenDevelop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders	Sovicille, Italy	Operational
DBDren BioClinical-stage biopharmaceutical firm focused on developing novel antibody therapeutics to target pathogenic cells and disease-causing agents	Foster City, United States	Acquired
NENeurophthDedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally	Wuhan, China	Operational
STSeekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients	Saint-Maur-des-Fossés, France	Operational
CICitryllDevelops therapeutics targeting the neutrophil extracellular trap (NET) pathway to treat inflammatory diseases, with its lead antibody, CIT-013, in clinical trials for rheumatoid arthritis and hidradenitis suppurativa	Oss, Netherlands	Operational

Showing 8 of the closest matchesCompare every metric →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

JCJiuyou Capital
CSChangjiang Securities
CCChengdu High-tech Ceyuan Capital
CIChengdu Bio-Town Investment
WIWuhan Optics Valley Industrial Investment
FCFC Capital
ICInnovation Capital
NLNLVC
YFYuanxi Haihe Fund

Series B and later1 investor entered at this stage

GVGuanghe VC

Other known investors1 additional known investor

DCDinghang Capital

Talent

Book a demo to see the people

Team profiled 2 named & role-tagged

Founders /100 quality score

Key operators 2 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

2 countries with
team presence

🇬🇧 United Kingdom66.7%

🇨🇳 China33.3%

2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Wuhan Ruijian Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Wuhan Ruijian Pharmaceutical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.